Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 274.48M | 268.09M | 251.23M | 187.58M | 181.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 274.48M | 268.09M | 251.23M | 187.58M | 181.49M |
| Cost of Revenue | 46.22M | 95.73M | 96.49M | 79.79M | 78.58M |
| Gross Profit | 228.26M | 172.36M | 154.74M | 107.79M | 102.91M |
| SG&A Expenses | 94.48M | 92.45M | 93.03M | 89.06M | 86.50M |
| Depreciation & Amortization | 32.55M | 32.71M | 32.87M | 33.03M | 33.03M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 173.25M | 220.89M | 222.39M | 201.88M | 198.11M |
| Operating Income | 101.23M | 47.20M | 28.85M | -14.30M | -16.63M |
| Income Before Tax | 184.88M | 158.96M | 62.98M | -84.50M | -161.11M |
| Income Tax Expenses | 31.32M | 34.51M | 14.40M | -8.63M | -28.49M |
| Earnings from Continuing Operations | 153.56 | 124.45 | 48.58 | -75.86 | -132.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 153.56M | 124.45M | 48.58M | -75.86M | -132.62M |
| EBIT | 101.23M | 47.20M | 28.85M | -14.30M | -16.63M |
| EBITDA | 134.91M | 81.44M | 63.50M | 20.19M | 18.62M |
| EPS Basic | 7.84 | 6.30 | 2.39 | -3.99 | -7.12 |
| Normalized Basic EPS | 6.53 | 4.64 | -0.57 | -2.60 | -2.70 |
| EPS Diluted | 7.36 | 5.82 | 2.07 | -4.00 | -7.12 |
| Normalized Diluted EPS | 6.18 | 4.29 | -0.68 | -2.61 | -2.70 |
| Average Basic Shares Outstanding | 78.51M | 77.82M | 77.07M | 75.91M | 74.61M |
| Average Diluted Shares Outstanding | 81.58M | 80.88M | 78.72M | 76.51M | 74.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |